Back to News
Market Impact: 0.2
Xencor, Inc. Selects 400 mcg/kg as Proposed Recommended Phase 3 Dose for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Xencor reported updated Phase 1 results for XmAb819, an ENPP3 x CD3 T-cell-engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma. Based on the results, the company selected 400 mcg/kg as the proposed intravenous recommended dose; the provided article text does not include further efficacy or safety details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
XNCR0.20
More News
- Stocks making the biggest moves midday: Lockheed Martin, JetBlue, CoreWeave, Surgery Partners & more
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Why is PagSeguro Digital stock plummeting 30% today?